Fresenius debuts subcutaneous formulation of biosimilar Tyenne
Fresenius, via its operating company Fresenius Kabi, is offering its biosimilar Tyenne (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment of chronic autoimmune diseases.
Tyenne is indicated for use in the treatment of chronic autoimmune diseases for certain indications of Chugai Seiyaku Kabushiki Kaisha's Actemra (tocilizumab).
Fresenius Kabi previously launched Tyenne in an intravenous formulation in April of this year.
[Read more: Fresenius Kabi obtains FDA OK for biosimilar Tyenne]
“After successfully launching Tyenne in more than 10 countries, we are on track to continue the momentum in the U.S with the launch of a second formulation,” said Sang-Jin Pak, president of Biopharma at Fresenius Kabi. “Introducing our subcutaneous formulation demonstrates our continued commitment to providing greater access to more patients living with autoimmune diseases.”
Tyenne is an FDA-approved tocilizumab biosimilar that is available in both intravenous and subcutaneous formulations. Tyenne received FDA approval on March 5, and an IV formulation was launched in April 2024 for use in the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis.
[Read more: Fresenius Kabi intros generic Tepadina]